Skip to content

Research Priorities for Pediatric Tuberculosis

This document (not a TAG publication) presents an overview of paediatric TB research efforts already underway and their limitations; and highlights priorities for future research initiatives in epidemiology, basic science, prevention, diagnosis, treatment and operational research.
Read more

No Time to Lose: G20 Leaders Must Fund R&D to End TB

In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).
Read more

LAM PEPFAR Request

February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded…

Read more

Tuberculosis Research at Risk as Big Pharma Shutters Programs

Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.
Read more
Back To Top